Merck Buys OncoImmune for $425 Million to Gain Covid Drug

Published November 23, 2020

Merck & Co. agreed to acquire privately held biopharma company OncoImmune for an upfront payment of $425 million in cash to gain a potential therapy for severe Covid-19.